Bexion Pharmaceuticals, Inc. today announced a Trials in Progress poster presentation at the American Society of Clinical Oncology Gastrointestinal Cancers Symposium (ASCO GI), being held January 18-20, 2024, in San Francisco, CA.
COVINGTON, Ky., Jan. 16, 2024 /PRNewswire/ -- Bexion Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company developing a new generation of biologic therapy to treat solid tumor cancers and chemotherapy-induced peripheral neuropathy (CIPN), today announced a Trials in Progress poster presentation at the American Society of Clinical Oncology Gastrointestinal Cancers Symposium (ASCO GI), being held January 18-20, 2024, in San Francisco, CA. Poster details are included below. Poster Details: Session Title: Trials in Progress Poster Session C: Cancers of the Colon, Rectum, and Anus “We are excited to present our ongoing trial of BXQ-350 in mCRC during the 2024 ASCO GI Symposium” said Scott Shively, CEO and President of Bexion Pharmaceuticals. “BXQ-350 in combination with FOLFOX and bevacizumab offers a unique opportunity to improve outcomes for 1st line patients with mCRC. We look forward to sharing progress with investigators and leaders at the conference.” About BXQ-350 About Bexion Pharmaceuticals Investor Contact: Media Contact: View original content to download multimedia:https://www.prnewswire.com/news-releases/bexion-pharmaceuticals-inc-announces-poster-presentation-at-asco-gi-2024-302035333.html SOURCE Bexion Pharmaceuticals, Inc. |